

Product Data Sheet

Product Name: Volociximab

Cat. No.: GC72366

Chemical Properties

Cas. No. 558480-40-3

Formula M.Wt 145.5 kDa (Average)

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Volociximab

Background

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin $\alpha 5 \beta 1$ (EC₅₀=0.2 nM). Integrin $\alpha 5 \beta 1$ is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).

Volociximab (20, 40, 80, 160, 320 nM) specifically targets integrin $\alpha 5 \beta 1$ (K_d=0.367 nM), but not integrin $\alpha 5 \alpha 5$ or $\beta 1 \beta 1$ [1].

Volociximab (0.01-100 nM; 4 d) inhibits the proliferation of human umbilical vein vascular endothelial

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cells (HUVEC) ($IC_{50}=0.2-0.5$ nM) and (10 μ g/mL; 16 h) induces apoptosis in schizogenic but not senescent Huvecs^[1].

Volociximab (0.067-67 nM; 6 d) inhibits 0.1 μ g/mL VEGF and/or bFGF induced HUVEC angiogenesis in vitro^[1].

Volociximab (300 μ g/eye; intravitreal injection; once weekly for 4 weeks) has well tolerance and inhibits angiogenesis in laser induced choroidal neovascularization (CNV) of cynomolgus monkey model^[1].

Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model^[2].

References:

[1]. Bhaskar V, et al. Volociximab, a chimeric integrin $\alpha 5\beta 1$ antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12.

[2]. Ramakrishnan V, et al. Preclinical evaluation of an anti- $\alpha 5\beta 1$ integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA